| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 10/26/2006 | US20060240166 Modified acacia and use thereof |
| 10/26/2006 | US20060240119 Pharmacologically active strong acid solutions |
| 10/26/2006 | US20060240118 Pharmacologically active strong acid solutions |
| 10/26/2006 | US20060240113 Anticancer agents; prevent forming blood vessels; removal blockager |
| 10/26/2006 | US20060240026 Preventing and/or remedy hematopoietic tumor |
| 10/26/2006 | US20060240023 Apoptosis-associated protein and use thereof |
| 10/26/2006 | US20060240022 Factor involved in metastasis and uses thereof |
| 10/26/2006 | US20060240015 Recombinant antibody against human insulin-like growth factor |
| 10/26/2006 | US20060240010 Methods of modulating CD200 receptors |
| 10/26/2006 | US20060240003 Humanised antibodies to the epidermal growth factor receptor |
| 10/26/2006 | US20060239990 Protein Arginine N-Methyltransferase 2 (PRMT-2) |
| 10/26/2006 | US20060239967 Oncolytic virus replicating selectively in tumor cells |
| 10/26/2006 | US20060239926 Specific high-relaxivity compounds |
| 10/26/2006 | US20060239912 Carrier molecules |
| 10/26/2006 | DE102005020105A1 New thiazolidinone compounds are polo-like kinase inhibitors, useful for the preparation of medicament to treat e.g. cancer, autoimmune disease, cardiovascular disease stenosis and infection disease |
| 10/26/2006 | DE102005020104A1 New thiazolidinone compounds are polo-like kinase inhibitors, useful for the preparation of medicament to treat e.g. cancer, autoimmune disease, cardiovascular disease stenosis and infection disease |
| 10/26/2006 | DE102005019094A1 New aza-heterocyclic compounds are tyrosine kinase inhibitor useful to prevent and/or treat cancer, tumor growth, tumor angiogenesis, arteriosclerosis, diabetic retinopathy and inflammation diseases |
| 10/26/2006 | DE102005017116A1 Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP) Inhibitors of inhibitors of apoptosis proteins (IAP) |
| 10/26/2006 | CA2675652A1 Dosage forms of risedronate |
| 10/26/2006 | CA2646257A1 Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients |
| 10/26/2006 | CA2610446A1 Nitrogen-containing heterocyclic compound |
| 10/26/2006 | CA2606174A1 Design and synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (bpu) sulfur analogs |
| 10/26/2006 | CA2606156A1 Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers |
| 10/26/2006 | CA2605617A1 Photodynamic therapy using chemiluminescence and a ligand-photosensitiser conjugate |
| 10/26/2006 | CA2604942A1 2-amino-quinaz0lin-5-ones |
| 10/26/2006 | CA2604933A1 Methods and compositions for modulating and detecting wisp activity |
| 10/26/2006 | CA2604907A1 Combination cancer therapy with bis(thiohydrazide) amide compounds |
| 10/26/2006 | CA2604821A1 2 -aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitor (iap) modulators |
| 10/26/2006 | CA2604805A1 Pyrrolobenzodiazepines |
| 10/26/2006 | CA2604393A1 Methods and compositions for treating or preventing cancer |
| 10/25/2006 | EP1715043A2 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 10/25/2006 | EP1715040A2 Zinc finger binding domains for GNN |
| 10/25/2006 | EP1715038A1 Antibody targeting osteoclast-associated protein |
| 10/25/2006 | EP1715035A2 Synthetic polynucleotides encoding lysyl oxidase |
| 10/25/2006 | EP1714981A2 Method for the identification of antigenic peptides |
| 10/25/2006 | EP1714979A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 10/25/2006 | EP1714978A1 Peptides useful for diagnosis and therapy of tumors |
| 10/25/2006 | EP1714970A1 Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity |
| 10/25/2006 | EP1714969A2 Immunostimulatory nucleic acid molecules |
| 10/25/2006 | EP1714961A1 Indazole compound and pharmaceutical use thereof |
| 10/25/2006 | EP1714653A1 Aqueous solution preparation containing camptothecins |
| 10/25/2006 | EP1714645A1 Pharmaceutical composition containing bakuchiol for treating breast cancer in women |
| 10/25/2006 | EP1714643A1 Sustained release preparation |
| 10/25/2006 | EP1713914A2 MEDICAL TREATMENT USING AN RNAi AGENT TARGETING A HUMAN NOTCH SIGNALLING PATHWAY MEMBER |
| 10/25/2006 | EP1713830A2 Anti-epcam immunoglobulins |
| 10/25/2006 | EP1713814A1 Bicyclic pyrazolo-fused compounds as protein kinase modulators |
| 10/25/2006 | EP1713798A2 C10 cyclopentyl ester substituted taxanes |
| 10/25/2006 | EP1713792A2 SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n- 4-METHYL-3 -(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL -BENZAMIDE |
| 10/25/2006 | EP1713785A1 Halogenated biaryl heterocyclic compounds and methods of making and using the same |
| 10/25/2006 | EP1713769A1 Amorphous tamsulosin hydrochloride |
| 10/25/2006 | EP1713543A2 Use of substituted 1,2,3 indolizine derivatives for treating diseases associated with a pathological angiogenesis |
| 10/25/2006 | EP1713542A2 COMBINATION OF (a) A DNA TOPOISOMERASE INHIBITOR AND (b) AN IAP INHIBITOR |
| 10/25/2006 | EP1713541A1 Use of alkaline phosphatase for the detoxification of lps |
| 10/25/2006 | EP1713511A1 Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same |
| 10/25/2006 | EP1713507A2 Adept or gdept production of acetaldehyde |
| 10/25/2006 | EP1713502A1 Highly concentrated liquid formulations of anti-egfr antibodies |
| 10/25/2006 | EP1713483A1 Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma |
| 10/25/2006 | EP1713481A2 Novel uses for proton pump inhibitors |
| 10/25/2006 | EP1713474A1 Indirubin derivatives having anticancer property against human cancer cell me |
| 10/25/2006 | EP1713461A1 Compounds having antitumor activity |
| 10/25/2006 | EP1713460A2 Fk228 analogs and their use as hdac-inhibitors |
| 10/25/2006 | EP1713337A2 Modulation of line-1 reverse transcriptase |
| 10/25/2006 | EP1554272B1 Benzimidazoles and benzothiazoles as inhibitors of map kinase |
| 10/25/2006 | EP1509498B1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same |
| 10/25/2006 | EP1495767B1 Immunoadjuvant |
| 10/25/2006 | EP1458718B1 Quinolinones as prostaglandin receptor ligands |
| 10/25/2006 | EP1430053B1 AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN |
| 10/25/2006 | EP1409525B1 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 10/25/2006 | EP1401824B1 Aromatic hydroxamic acid derivatives useful as hdac inhibitors |
| 10/25/2006 | EP1383511B1 Calcilytic compounds |
| 10/25/2006 | EP1326617B9 Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of a medicament for the treatment fo breast, ovarian, endometrial cancer, myeloma and meningioma |
| 10/25/2006 | EP1219632B1 Steroids, their preparation, pharmaceutical compositions thereof and uses of the compounds |
| 10/25/2006 | EP1187613B9 Amide substituted imidazoquinolines |
| 10/25/2006 | EP1089998B1 Epothilone derivatives and their synthesis and use |
| 10/25/2006 | EP0828849B1 High-affinity oligonucleotide ligands to pdgf |
| 10/25/2006 | CN1852988A Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation |
| 10/25/2006 | CN1852979A Modulation of eIF4E expression |
| 10/25/2006 | CN1852923A Human antibody molecules for IL-13 |
| 10/25/2006 | CN1852914A Novel indolopyrrolocarbazole derivative with antitumor activity |
| 10/25/2006 | CN1852905A N-substituted benzimidazolyl c-kit inhibitors |
| 10/25/2006 | CN1852740A Multi-arm polymer prodrugs |
| 10/25/2006 | CN1852738A Treatment of gastrointestinal stromal tumors with imatinib and midostaurin |
| 10/25/2006 | CN1852737A Combination of a histone deacetylase inhibitor with a death receptor ligand |
| 10/25/2006 | CN1852730A Modulators of P-selectin glycoprotein ligand 1 |
| 10/25/2006 | CN1852729A Antibacterial drug for propionibacterium acnes |
| 10/25/2006 | CN1852720A Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist |
| 10/25/2006 | CN1852719A Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate |
| 10/25/2006 | CN1852716A Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone |
| 10/25/2006 | CN1852709A Macrophage activation inhibitor |
| 10/25/2006 | CN1852708A Human beta-defensin secretion promoter |
| 10/25/2006 | CN1850859A Angiogenin mutant as agonist, and its preparing method |
| 10/25/2006 | CN1850857A Rana grahami propyl sperm peptide, gene and variant and its pharmaceutical use |
| 10/25/2006 | CN1850849A 25-hydroxy dioscin ketone, and its preparing method and use |
| 10/25/2006 | CN1850847A Method for preparing periplogenin |
| 10/25/2006 | CN1850845A 3beta, 5 alpha, 6 beta, 11 beta tetrahydroxy cholestanol, and its preparing method and use |
| 10/25/2006 | CN1850828A Podophyllotoxin derivatives and their preparing method |
| 10/25/2006 | CN1850826A Eremophil dilactone natural product with tumour cell growth inhibiting activity |
| 10/25/2006 | CN1850825A Eremophil dilactone with tumour cell growth inhibiting activity and its use |
| 10/25/2006 | CN1850824A Benzene-free tetrandrine and its preparing method |
| 10/25/2006 | CN1850817A Roofirisrhizome flavin non polar isostere, and its preparing method and use |